

# LABORATORY SERVICES

## MEMORANDUM

DATE: December 19, 2007

TO: SFH and SFS Physicians

FROM: Virginia Burdine, MD, PhD, SFH Transfusion Service Medical Director

SUBJECT: Change in Primary Plasma Product to FP24

Effective January 15, 2008, plasma frozen within 24 hours (FP24) will become the primary plasma product for Saint Francis Hospital and Saint Francis South Hospital. This reflects a national change in manufacturing in an effort to reduce the risk of transfusion-related acute lung injury (TRALI) by excluding female plasma donors.

As approved by the SFH Medical Executive Committee, orders for FFP will be automatically filled with FP24, unless FFP is approved in advance by the Transfusion Service Medical Director. Apheresis FFP will be available in limited quantities and may be used for large volume therapeutic plasma exchanges.

The clinical efficacy of FP24 is essentially the same as FFP. The only measurable difference is a 15-20% decrease in Factor VIII levels. Factor VIII concentrates should be used to specifically replace Factor VIII; cryoprecipitate should be used to specifically replace fibrinogen.

Questions may be directed to Virginia Burdine, MD, at 494-1420 or Gary Eastburn at 494-6544.